Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Heron Therapeutics Inc’s stock clocked out at $1.88, down -1.57% from its previous closing price of $1.91. In other words, the price has decreased by -$1.57 from its previous closing price. On the day, 0.67 million shares were traded.
Ratios:
To gain a deeper understanding of HRTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.76 and its Current Ratio is at 2.40.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Rodman & Renshaw on June 13, 2024, initiated with a Buy rating and assigned the stock a target price of $7.
On April 23, 2024, CapitalOne started tracking the stock assigning a Overweight rating and target price of $6.
Needham reiterated its Buy rating for the stock on March 13, 2024, while the target price for the stock was revised from $4 to $5.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.93.
Stock Price History:
Over the past 52 weeks, HRTX has reached a high of $3.93, while it has fallen to a 52-week low of $1.04. The 50-Day Moving Average of the stock is -9.75%, while the 200-Day Moving Average is calculated to be 1.42%.
Shares Statistics:
A total of 152.43M shares are outstanding, with a floating share count of 151.14M. Insiders hold about 0.93% of the company’s shares, while institutions hold 82.00% stake in the company.
